Tags : Acquire

M&A MedTech

Avantor to Acquire Ritter and its Affiliates for ~$1.06B

Shots: Avantor to acquire Ritter and its affiliates in an all-cash transaction with an up front equity purchase price of ~ $1.06B along with additional payments following the achievement of milestones. The transaction is expected to be completed in Q3’21 The acquisition expands Avantor’s offering for diagnostic and drug discovery workflows The acquisition integrates Ritter’s […]Read More

M&A MedTech

DiaSorin to Acquire Luminex for ~$1.8B

Shots: DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, 2021, making a total equity value of $1.8B The acquisition will boost DiaSorin’s presence in the molecular diagnostics space in the US with the addition of Luminex’s molecular diagnostics multiplexing […]Read More

DigiHealth M&A

Microsoft to Acquire Nuance for ~$19.7B

Shots: Microsoft to acquire all outstanding shares of Nuance for $56.00/ share, making a total deal value of $19.7B in cash with a premium of 23% to Nuance closing price on Apr 09, including its net debt. The transaction is expected to close in 2021 The acquisition builds on Microsoft’s efforts to deliver new cloud […]Read More

M&A

Sanofi to Acquire Tidal Therapeutics for ~$470M

Shots: Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones The acquisition will add Tidal’s innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas With its acquisition, Sanofi will further develop the technology platform to expand its research capabilities in immuno-oncology and […]Read More

M&A MedTech

Hologic to Acquire Mobidiag for ~ $795M

Shots: Hologic to acquire Mobidiag for ~$795M which includes ~$714M in cash for Mobidiag’s equity and debt of $81M. The acquisition is expected to close in Q4’21 The acquisition will accelerate Hologic’s global footprints by enabling it to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of […]Read More

M&A

Sorrento to Acquire ACEA Therapeutics for ~$488M

Shots: ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones along with 5 – 10% royalties based on annual sales of each product. The acquisition is expected to close in Q2’ 21 The acquisition includes Abivertinib, AC0058, AC0939, and ACEA’s […]Read More

M&A

Amgen to Acquire Rodeo Therapeutics for ~$721M

Shots: Amgen to acquire all outstanding shares of Rodeo for a $55M upfront along with ~$666M in cash as contingent milestones The acquisition will strengthen Amgen’s inflammation portfolio with the addition of Rodeo’s 15-PGDH program Rodeo’s 15-PGDH has the potential in its preclinical studies and have clinical potential in multiple indications Click here to­ read full […]Read More

M&A

Merck to Acquire Alydia Health for ~$240M on Behalf of

Shots: Organon to acquire Alydia Health for up to $240M including $215M up front out of which $50 will be paid prior to the spinoff of Organon, $165 will be paid on the closure of the acquisition while remaining will be paid upon achievement of the milestones. Alydia will also receive ~$25M as a contingent […]Read More